FLDM Fluidigm

Fluidigm to Offer Millions of Advanta COVID-19 Tests at Low Cost to U.S. Colleges and Universities

Fluidigm to Offer Millions of Advanta COVID-19 Tests at Low Cost to U.S. Colleges and Universities
EN
08/10/2020

Underlying

FLDMFluidigm

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Fluidigm

 PRESS RELEASE
Free
FLDM FLUIDIGM

Standard BioTools Enters Next Phase of Transformation with Strategic S...

Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina Up To $425 Million In Total Proceeds Inclusive of Near-term Milestone Payments; $350 Million In Upfront Cash   Retains Strategic Upside with Illumina Protein Prep Royalty Stream and Rights to Single SOMAmer Reagent Business   Simplifies Operating Structure and Enables Achievement of Adjusted EBITDA Break-Even    Cash & Cash Equivalents of At Least $550 Million Expected at Close to Fuel Inorganic Growth Strategy and Drive Long-Term Value Creation SOUTH SAN FRANCISCO, Calif., June 23, 2025 (...

June 23, 2025 1 EN
 PRESS RELEASE
Free
FLDM FLUIDIGM

Standard BioTools to Host Inaugural “Proteomics Roundtable” Webcast Se...

Standard BioTools to Host Inaugural “Proteomics Roundtable” Webcast Series Featuring top researchers and industry experts using high-throughput proteomics to drive breakthroughs in population health, translational research and clinical development SOUTH SAN FRANCISCO, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced the launch of its inaugural – a program of virtual events designed to spark conversation about the rapidly evolving field of proteomics. The series will spotlight thought leaders and industry experts discussing groundbreaking res...

May 30, 2025 1 EN
 PRESS RELEASE
Free
FLDM FLUIDIGM

Standard BioTools Reports First Quarter 2025 Financial Results

Standard BioTools Reports First Quarter 2025 Financial Results SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the first quarter ended March 31, 2025. Recent Highlights: First quarter 2025 revenue of $40.8 million45% reduction in operating loss and 29% improvement in adjusted EBITDA year-over-yearOperationalized $10 million more in annual run rate cost reductions, totaling $90 million since merger Strong balance sheet with $261 million in cash & cash equiva...

May 6, 2025 1 EN
 PRESS RELEASE
Free
FLDM FLUIDIGM

Standard BioTools Announces New Product Innovations in Plasma and Sing...

Standard BioTools Announces New Product Innovations in Plasma and Single-Cell Proteomics at AACR 2025 Expanded suite of consumables, instruments and services designed to empower researchers and accelerate next-generation drug development Ninety posters and presentations at AACR powered by the Standard BioTools proteomic portfolio to advance cancer research from target discovery to clinical development SOUTH SAN FRANCISCO, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced the launch of new and enhanced proteomic product offerings at the upcom...

April 24, 2025 1 EN
 PRESS RELEASE
Free
FLDM FLUIDIGM

Standard BioTools Schedules First Quarter Earnings Conference Call on ...

Standard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025 SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report first quarter 2025 financial results on Tuesday, May 6, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress. Individuals can access the conference call by dialing: US domestic callers: (888) 346-3970Outside US callers: (412) 902-4297 Live audio of the webca...

April 22, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch